Mepindolol reduces myocardial necrosis in rats with coronary artery occlusion.
Mepindolol is a newly developed beta-adrenergic blocking agent reported to counteract the chronotropic effect of catecholamines, with only little effect on contractility. This study was designed to assess whether or not mepindolol is effective in reducing infarct size. Accordingly, 16 rats, serving as controls, underwent coronary artery occlusion and did not receive any treatment; an additional 19 were treated with mepindolol (1 mg/kg s.c. t.i.d.) for 48 h. Finally, a third group (n = 18) underwent sham operation. Forty-eight hours later, infarct size was calculated from left ventricular creatine phosphokinase activity and found to average 52.4 +/- 7.8% (mean +/- SEM) of the left ventricle in control rats and 35.6 +/- 5.4% in treated rats (p less than 0.05). Left ventricular phospholipid content averaged 0.79 +/- 0.08 microgram P/mg protein in sham-operated rats and 0.61 +/- 0.04 microgram P/mg protein in control animals. In contrast, in mepindolol-treated rats, phospholipid concentration was 0.70 +/- 0.04 microgram P/mg protein (p less than 0.05), this suggesting a protective effect of the drug on ischemia-induced phospholipid degradation. The long-term effect of mepindolol on left ventricular hydroxyproline concentration was assessed 21 days post-coronary occlusion. Infarct size calculated by this method was 30.2 +/- 4.8% of left ventricle in 21 control animals and 18.2 +/- 4.2% in 28 treated rats (p less than 0.05), indicating that, as for the acute necrosis, the extent of scar development after coronary artery occlusion can be reduced by mepindolol.
M
M
Chiariello
G
G
Ambrosio
M
M
Cappelli-Bigazzi
P
P
Perrone-Filardi
I
I
Tritto
G
G
Marone
M
M
Condorelli
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000473:pathology*; D003094:Collagen / Q000032:analysis; D003331:Coronary Vessels; D003402:Creatine Kinase / Q000378:metabolism; D006909:Hydroxyproline / Q000032:analysis; D007527:Isoenzymes; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology; D009206:Myocardium / Q000201:enzymology / Q000473:pathology*; D009336:Necrosis; D010740:Phospholipases / Q000037:antagonists & inhibitors; D010743:Phospholipids / Q000032:analysis; D010869:Pindolol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D007527:Isoenzymes; D010743:Phospholipids; C015340:mepindolol; D003094:Collagen; D010869:Pindolol; D003402:Creatine Kinase; D010740:Phospholipases; D006909:Hydroxyproline